Physician profile
John L Cecconi
NPI 1477934362
$3,127.06
in general payments reported to CMS, 2019-2025
29 companies · $913 in 2025
The $913 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.65 · 2020: $120 · 2021: $358 · 2022: $461 · 2023: $455 · 2024: $757 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870 · Travel and Lodging: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.08 |
| Travel and Lodging | $255.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $495.65 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $321.67 | 2019-2025 | |
| Lilly USA, LLC | $308.31 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $306.78 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Regeneron Pharmaceuticals, INC. | $292.31 | 2025 | |
| Glaxosmithkline, LLC. | $245.67 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $217.94 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.91 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Exact Sciences Corporation | $120.44 | 2024-2025 | Cologuard Collection Kit |
| Insulet Corporation | $71.46 | 2024-2025 | Omnipod |
| Gilead Sciences, INC. | $59.36 | 2024-2025 | |
| Allergan, INC. | $48.19 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.61 | 2021 | |
| Dexcom, INC. | $45.48 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $39.98 | 2025 | Auvelity |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $39.07 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.72 | 2025 | Caplyta |
| Paratek Pharmaceuticals, INC. | $31.05 | 2022-2024 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.10 | 2022-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $27.89 | 2020-2021 | |
| Ibsa Pharma INC. | $26.78 | 2023-2025 | Tirosint, Flector, Licart |
| Merck Sharp & Dohme LLC | $25.60 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $24.70 | 2022 | |
| Shield Therapeutics INC | $21.39 | 2023 | Accrufer |
| Novartis Pharmaceuticals Corporation | $20.22 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.15 | 2023 | |
| Dynavax Technologies Corporation | $18.82 | 2022 | |
| Inspire Medical Systems, INC. | $17.43 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $12.38 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cecconi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.